Combined Screening with PLGF (DELFIA) – BioValues

BioValues – Advanced Prenatal Screening for Early Risk Assessment

The Combined Screening with PLGF (DELFIA) test is an advanced first-trimester prenatal screening test used to assess the risk of chromosomal abnormalities and pregnancy-related complications in the developing fetus. This screening combines maternal blood biomarkers with ultrasound findings to provide accurate early pregnancy risk evaluation.

The test measures:

• PAPP-A (Pregnancy-Associated Plasma Protein-A)
• Free β-hCG (Beta Human Chorionic Gonadotropin)
• PLGF (Placental Growth Factor)

These markers, together with Nuchal Translucency (NT) scan findings, maternal age, and gestational age, help estimate the risk for:

• Down Syndrome (Trisomy 21)
• Edwards Syndrome (Trisomy 18)
• Patau Syndrome (Trisomy 13)
• Early detection risk for Preeclampsia
• Placental dysfunction-related complications

Test Highlights

• Advanced first-trimester prenatal screening
• Includes PLGF biomarker for enhanced assessment
• Helps identify high-risk pregnancies early
• Non-invasive maternal blood test
• Improved predictive accuracy using DELFIA technology
• Supports timely medical monitoring and pregnancy care

Recommended For

• Pregnant women between 11 to 13 weeks + 6 days gestation
• Women with advanced maternal age
• High-risk pregnancy monitoring
• Patients advised for fetal chromosomal screening
• Early preeclampsia risk assessment

Specimen Required

• Maternal blood sample (Serum)

Technology Used

• DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay)

Preparation

• No fasting required
• Ultrasound NT scan details may be needed for accurate interpretation

Benefits of the Test

• Early reassurance during pregnancy
• Better pregnancy management planning
• Supports informed clinical decisions
• Helps obstetricians identify pregnancies requiring closer monitoring

Note

This is a screening test, not a diagnostic confirmation test. Positive or high-risk results may require further evaluation such as NIPT or invasive diagnostic testing under medical guidance.